The study of the effectiveness of the spray Fungin Forte in the treatment of dermatophytosis in cats

This article presents a study of the effectiveness of the spray Fungin Forte (developed by LLC API-SAN) in the complex therapy of dermatophytosis in cats on a group of 20 animals infected spontaneously. Terbinafine in oral form in tablets was used as a fungicidal preparation and Fungin Forte samples in the form of a spray were used for local processing. The criteria for clinical efficacy were the results of an examination with a planimetry, which noted a reduction and change in the affected skin lesions, a decrease in the degree of itching (using a standard 10-point scale to assess itching), erythema, peeling, hair growth, and a negative mycological study conducted on DTM environment. The total therapeutic efficacy by the thirtieth day was 95 %, which allows the use of the spray as a local fungicide.

Download Full-text

Therapeutic efficacy of topical luliconazole versus topical ketoconazole in the treatment of pityriasis versicolor patients: a hospital based comparative study

International Journal of Research in Dermatology ◽

10.18203/issn.2455-4529.intjresdermatol20200606 ◽

2020 ◽

Vol 6 (2) ◽

pp. 248

Author(s):

Shahid Hassan ◽

Ashutosh Ranjan

Keyword(s):

Comparative Study ◽

Clinical Efficacy ◽

Therapeutic Efficacy ◽

Skin Lesions ◽

Similar Efficacy ◽

Pityriasis Versicolor ◽

Male Population ◽

Treatment Regimens ◽

Mycological Examination

Background: To evaluate the clinical efficacy of 1% topical luliconazole versus 2% topical ketoconazole in pityriasis versicolor patients.Methods: Mycological examination of all the pityriasis versicolor patient was done by using skin scrapings were collected from the skin lesions to prepare for 10% KOH mount, which was examined under the microscope to note the findings as KOH mount positive or negative for Malassezia fungi. KOH mount positive or negative was noted at 0 days, 2 weeks and 4 weeks continued treatments with luliconazole and ketoconazole.Results: At the first days, majorities of patients 46 (92%) of luliconazole group were positive for KOH mount. At 14 days treatment with luliconazole, patients had 11 (22%) positive for KOH mount. At the 28 days treatment with luliconazole, only 2 (4%) patients were positive and most of the patients 49 (98%) were negative for KOH mount. Similarly, in ketoconazole group patients, 47 (94%) patients were positive for KOH mount in beginning of treatment. At 14 days treatment with ketoconazole 16 (32%) patients were positive and 34 (68%) patients were negative for KOH mount. And at the 28 days with treatment of ketoconazole 13 (26%) patients were positive and most of the patients 37 (74%) were negative for ketoconazole.Conclusions: Male population as well as age 26-35 years were more prone for pityriasis versicolor infection. On two weeks of treatment luliconazole and ketoconazole had near about similar efficacy against pityriasis versicolor. But, on continue 4 weeks of treatment regimens topical luliconazole had more clinically efficacious than ketoconazole against pityriasis versicolor.

Download Full-text

Clinical efficacy of the drug 200 mg silver proteinate in the complex therapy of acute infectious rhinitis in children, which occurred as part of an acute respiratory infection

Russian otorhinolaryngology ◽

10.18692/1810-4800-2021-4-88-95 ◽

2021 ◽

Vol 20 (4) ◽

pp. 88-95

Author(s):

A. B. Kiselev ◽

◽

Kh. T. Abdulkerimov ◽

N. E. Terskova ◽

V. A. Chaukina ◽

...

Keyword(s):

Comparative Study ◽

Pharmaceutical Company ◽

Respiratory Infection ◽

Nasal Spray ◽

Clinical Efficacy ◽

Acute Respiratory Infection ◽

Quality Of Treatment ◽

Complex Therapy

The effectiveness of pharmacotherapy of acute infectious rhinitis in children by means of drugs from the list of medicines of the J00 Standard and in addition to this pharmacotherapy with the drug silver proteinate – 200 mg nasal spray Sialor® (manufacturer of JSC «Production Pharmaceutical Company “Obnovlenie”, Russia) was evaluated in a multicenter randomized comparative study. A higher quality of treatment was demonstrated when using 200 mg silver proteinate (Sialor®) in the form of a nasal spray in complex therapy. The article presents evidence of the feasibility of including the drug 200 mg silver proteinate in the list of medicines of the J00 Standard.

Download Full-text

Clinical efficacy of popular oral hair growth supplement ingredients

International Journal of Dermatology ◽

10.1111/ijd.15344 ◽

2020 ◽

Author(s):

Madeline J. Adelman ◽

Lisa M. Bedford ◽

Geoff A. Potts

Keyword(s):

Clinical Efficacy ◽

Hair Growth ◽

Growth Supplement

Download Full-text

The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with Atopic Dermatitis (AD) treated with cyclosporine or prednisone

Polish Journal of Veterinary Sciences ◽

10.2478/v10181-010-0005-4 ◽

2010 ◽

Vol 13 (4) ◽

pp. 681-688 ◽

Cited By ~ 3

Author(s):

I. Taszkun

Keyword(s):

Atopic Dermatitis ◽

Severity Index ◽

Skin Lesions ◽

Clinical State ◽

Point Scale ◽

Canine Atopic Dermatitis ◽

Group I ◽

Oral Preparation ◽

Sandimmun Neoral ◽

Anti Inflammatory

The evaluation of Canine Atopic Dermatitis Extent and Severity Index (CADESI) test in dogs with Atopic Dermatitis (AD) treated with cyclosporine or prednisone The purpose of this study was to assess the clinical state of dogs with atopic dermatitis (AD) by use of CADESI test in own modification during the first visit in the Dermatology Consult Room as well as during the treatment. The study was performed in two groups (I-E and II-C) of 20 dogs in each group. In dogs which were qualified to the I-E group, as antiallergic, anti-inflammatory and antipruritic treatment, prednisone (oral preparation Encorton - Polfa Pabianice) at dose 0.5 mg/kg b.w./day was administered, while in dogs qualified to the II-C group - cyclosporine (oral preparation Sandimmun Neoral - Novartis Pharma) at a dose of 5 mg/kg b.w./day; the treatment was continued for 6 weeks in both groups. During the study, skin lesions were assessed in 15 specified body areas using 4 parameters and 5-point scale. In group I-E and II-C the amount of received points in CADESI test was decreased by 82.26% and by 83% respectively, after the treatment. Statistical analyses of the results obtained revealed no statistically significant (P=0.05) differences between means of I-E and II-C groups in consecutive examinations, which indicates comparable clinical efficacy of both drugs. Statistically significant differences (P=0.05) of the parameters assessed were found after secondary dermatoses treatment, and after every two weeks of antipruritic and anti-inflammatory treatment.

Download Full-text

Complex therapy of a multimorbid patient: focus on the reproducible drugs

Consilium Medicum ◽

10.26442/20751753.2021.6.200922 ◽

2021 ◽

Vol 23 (6) ◽

pp. 498-503

Author(s):

Vera N. Larina ◽

Keyword(s):

Pharmaceutical Company ◽

Therapeutic Efficacy ◽

Generic Drugs ◽

Stable Coronary Artery Disease ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Noncommunicable Diseases ◽

Complex Therapy ◽

Medicinal Substances ◽

Artery Disease

Chronic noncommunicable diseases are associated with high mortality and high costs of medical care, and therefore require safe, effective and affordable therapy. When choosing a generic drug, a doctor may be guided by the assumption that the bioequivalence of medicinal substances is an indirect confirmation of their therapeutic efficacy. Absolute confidence in the same efficacy of original and generic drugs can only emerge after welldesigned studies comparing therapeutic equivalence. The results of the Russian multicenter, open, randomized KARDIOKANON study, the purpose of which was to compare two options for complex therapy based on the use of only original or only generic drugs in persons with stable coronary artery disease, showed the comparability of the effectiveness of original and reproducible drugs of the pharmaceutical company “Canonpharma Production” in achieving the target value of arterial pressure, heart rate, low density lipoprotein and impact on quality of life. A sufficient variety of drugs produced by this pharmaceutical company opens up opportunities for the appointment of any of them, but further large controlled studies are needed to finally confirm the bioequivalence, therapeutic efficacy and interchangeability of original and reproducible drugs.

Download Full-text

CLINICAL EFFICACY OF RIZENDRONATE ACID IN THE COMPLEX THERAPY OF PATIENTS WITH OSTEOARTHRITIS AND METABOLIC SYNDROME

Medical Herald of the South of Russia ◽

10.21886/2219-8075-2017-1-65-69 ◽

2017 ◽

pp. 65-69

Author(s):

D. I. Lakhin ◽

L. V. Vasilyeva

Keyword(s):

Metabolic Syndrome ◽

Clinical Efficacy ◽

Complex Therapy

Download Full-text

EMOLLIENT MILK XEMOSE IN THERAPY OF ATOPIC DERMATITIS IN CHILDREN

Rossiiskii Allergologicheskii ZHurnal ◽

10.36691/rja629 ◽

2014 ◽

Vol 11 (4) ◽

pp. 59-63

Author(s):

E T KINDEEVA ◽

N G KOROTKII ◽

A N PAMPURA

Keyword(s):

Atopic Dermatitis ◽

Clinical Efficacy ◽

Combined Therapy ◽

Allergic Inflammation ◽

Skin Barrier ◽

Skin Surface ◽

Skin Lesions ◽

Transepidermal Water Loss ◽

Skin Barrier Function ◽

Epidermal Barrier

Background. Structural and functional damages of the epidermal barrier in patients with atopic dermatitis promote the entry of allergens and development of Th2-type allergic inflammation. Moisturizers containing lipids increase the physiological antiinflammatory effects of topical corticosteroids (TGKS), improve the epidermal barrier and reduce the duration of TGKS using preventing further infringement barrier. To evaluate the clinical efficacy of emollient milk Xemose in children with atopic dermatitis. Materials and methods. We examined 27 children with atopic dermatitis. Children were divided into 2 groups: patients in group 1 (n=14) used emollient milk Xemose twice a day on the skin lesions and limbs in the complex therapy, patients in the 2nd group (n=13) received combined therapy incorporating traditional dampening agents on the basis of lanolin (Unna cream) 3 times daily. All patients underwent measurement of transepidermal water loss (TEWl) (Tewameter TM 300, Multi Probe Adapter MPA 5/9, Courage + Khazaka) and the pH of the skin (Skin-pH-Meter, Multi Probe Adapter MPA 5/9, Courage + Khazaka) before and after 2 weeks of therapy. Results. Patients in groupthat used Xemose milk and children in group with Unna cream after 2 weeks showed a statistically significant decrease of TEWl (p=0,041 and p=0,04, respectively). TEWl was significantly lower in children treated for 2 weeks with milk Xemose (p=0,027) than in children treated with Unna cream. in both groups pH skin surface have not changed (р=0,22 and р=0,22 respectively). Conclusion. Clinical efficacy of milk Xemose as compound improving skin barrier function in children with atopic dermatitis was shown.

Download Full-text

Experimental Study of Therapeutic Efficacy of the Topical Preparation «Kourochitin» in Skin Allergy

Letters in Drug Design & Discovery ◽

10.2174/1570180817666200316155643 ◽

2020 ◽

Vol 17 (10) ◽

pp. 1237-1244

Author(s):

Anna Anatolievna Klimovich ◽

Olga Nikolaevna Styshova ◽

Alexander Mikhailovich Popov ◽

Tatiana Vladimirovna Moskvina ◽

Alexander Vasilevich Tsybulsky ◽

...

Keyword(s):

Therapeutic Efficacy ◽

Protective Action ◽

Skin Lesions ◽

Skin Area ◽

Immunological Parameters ◽

Experimental Animals ◽

Allergic Skin ◽

Curative Action ◽

Macrophage Colony ◽

Allergic Contact

Background: The researchers of PIBOC RAS developed the dermo-protective topical drug called «Kourochitin», active substance of which is known quinazoline alkaloid tryptanthrin. In the present work, therapeutic efficacy of this drug in the treatment of allergic dermatosis was evaluated. Methods: Dermo-protective action of «Kourochitin» was studied in tow murine models: 2, 4- dinitrofluorobenzene- induced allergic contact dermatitis (ACD) and imiquimod-induced psoriasis. Results and Discussion: In a model ACD, it was shown that «Kourochitin» exhibits the curative action on pathophysiological, hematological and immunological parameters in ACD. Namely, «Kourochitin» 1) reduces the level of erythema in the allergen damaged skin area and increases the healing index of the epidermis; 2) normalizes the content of eosinophils, basophils and monocytes in the blood of experimental animals; 3) inhibits the production of main pro-inflammatory cytokines: interleukins - 1 and 2, interferon-gamma, and granulocyte-macrophage colony-stimulating factor. In a murine model of imiquimod-induced psoriasis, it was shown that «Kourochitin» application led to reduction in psoriasis severity on the inflamed epidermis of experimental animals. Additionally, in veterinary research, «Kourochitin»-treatment of canine atopic dermatitis almost completely eliminated signs of allergic manifestations on the epidermis. Conclusion: The obtained data suggest that «Kourochitin» as anti-inflammatory, anti-allergic, and wound healing remedy is a potential drug for therapy of various dermatological diseases, in particular allergic skin lesions.

Download Full-text